RETRACTED: Anti-relapse chemotherapy in liver echinococcosis

Abstract

RETRACTED ARTICLEStudy objective – the effectiveness of clinical-based schemes of Albendazole anti-relapse chemotherapy. We studied the long-term results of surgical treatment of 709 patients with various forms of liver echinococcosis. Depending on the scheme of preventive treatment, the patients were divided into four groups. The fifth (control) group consisted of patients who did not receive anti-relapse chemotherapy with Albendazole. The recurrence frequency was evaluated by the survey 3–3,5 years after surgery. We found that Albendazole preventive treatment significantly reduces the relapse rate within 3–3,5 years after surgery. In the control group, relapse occurred in 42 cases (8,1%) (χ2 =10,6; р=0,0012), compared to 2 relapse cases in the study groups (1,1%). Aparasitic and antiparasitic regimes are necessary but not sufficient to prevent recurrence. The isolated relapse cases in various Albendazole preventive treatment schemes demonstrated no clear advantage of any scheme.

Keywords

• liver echinococcosis
• liver hydatid disease
• relapse
• albendazol